Zafirlukast has no beneficial effects in the treatment of chronic urticaria
Article first published online: 11 DEC 2002
Clinical & Experimental Allergy
Volume 32, Issue 12, pages 1763–1768, December 2002
How to Cite
Reimers, A., Pichler, C., Helbling, A., J. Pichler, W. and Yawalkar, N. (2002), Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clinical & Experimental Allergy, 32: 1763–1768. doi: 10.1046/j.1365-2222.2002.01536.x
- Issue published online: 11 DEC 2002
- Article first published online: 11 DEC 2002
- Submitted 30 November 2001; revised 3 July 2002; accepted 7 August 2002
- chronic urticaria;
- leukotriene receptor antagonist;
Background Leukotriene receptor antagonists have shown some efficacy in the treatment of asthma. Injection of LTC4, LTD4 and LTE4 into the skin leads to a weal-and-flare reaction, suggesting an involvement of leukotrienes in the pathogenesis of urticaria. Indeed, various reports have indicated a beneficial effect for leukotriene receptor antagonists in patients with chronic urticaria.
Objective To determine the therapeutic effect of the leukotriene receptor antagonist zafirlukast in patients with chronic urticaria.
Methods The study was a double-blind, placebo-controlled, cross-over study lasting for 12 weeks. Fifty-two patients with chronic urticaria were investigated at a university hospital. The patients were randomized to receive 20 mg zafirlukast b.i.d. or placebo and cross-over was scheduled after 6 weeks. The efficacy of the treatment was evaluated by a daily symptom score, six physical examinations, the requirement of rescue antihistamines (acrivastine) and an overall assessment by the patient and the investigating physician.
Results Forty-six patients completed the study: zafirlukast was well tolerated without alteration of the investigated laboratory parameters. In comparison with placebo, treatment with zafirlukast resulted in no significant positive effect for any of the efficacy measures. Moreover, we were unable to identify any subgroup of patients with chronic urticaria responding with a therapeutic benefit.
Conclusions The leukotriene receptor antagonist zafirlukast does not provide a significant therapeutic benefit at a dose of 20 mg b.i.d. in patients with chronic urticaria.